Stay updated with breaking news from Deciphera Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) – Equities researchers at SVB Leerink reduced their FY2026 earnings per share estimates for Deciphera Pharmaceuticals in a note issued to investors on Wednesday, January 4th. SVB Leerink analyst A. Berens now expects that the company will earn $3.38 per share for the year, down from their previous […]
Equities analysts expect Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) to report earnings of ($0.84) per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Deciphera Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.11) and the highest is ($0.61). Deciphera Pharmaceuticals posted earnings per share of ($1.06) during […]
Brokerages predict that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) will announce sales of $26.82 million for the current quarter, Zacks reports. Seven analysts have provided estimates for Deciphera Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $22.80 million and the highest estimate coming in at $30.00 million. Deciphera Pharmaceuticals reported sales of […]
Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.
– QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study – ... | December 22, 2021